🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

Gonorrhoea infections are escalating globally, with estimates suggesting over 82 million infections annually. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the face of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Gain Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Data and Worldwide Availability

As per data released by a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which uses a dual-drug approach. The study enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced hope. Having a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.